RecruitingNCT04979156

LaserEn: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors


Sponsor

University of Kansas Medical Center

Enrollment

20 participants

Start Date

Nov 4, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Conventional monopolar or bipolar transurethral resection of bladder tumors is the most common method for resection of a bladder mass. En bloc resection has demonstrated success in the literature utilizing different techniques and lasers, including utilizing the Ho:YAG and Tm:YAG lasers. A recent metanalysis revealed several benefits to laser en bloc resection including less complications and lower recurrence rate.22 Subsequently, laser technology has also advanced with the development of a super pulsed TFL which overcomes many limitations of prior traditional lasers. Olympus' SOLTIVE™ TFL, which has demonstrated improved maneuverability and control, has a shallow depth of tissue penetration at 0.15mm leading to precise resection and optimal hemostasis. Despite these beneficial characteristics and qualities along with the promising utility of en bloc resection, the Olympus SOLTIVE™ TFL has not been described in en bloc resection of bladder tumors. The investigator seek to determine if the proposed benefits of this device can be realized both pathologically and clinically in en bloc resection of bladder tumors.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Patients must be 18 years of age or older.
  • Patient presenting for resection of papillary bladder tumor visualized on cystoscopy
  • New bladder tumor
  • Recurrent tumors
  • Tumor \<3cm

Exclusion Criteria2

  • Patient unwilling to undergo en bloc resection
  • Non papillary lesions/tumors

Interventions

PROCEDURESOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors

SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors


Locations(1)

University of Kansas Medical Center

Kansas City, Kansas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04979156


Related Trials